In this week's EuroBiotech Report, AstraZeneca rejected by FDA, Novartis fails phase 3, Pulmocide raises $30 million and more.

In our EuroBiotech roundup this week, AB shares jump on phase 3 ALS data, Advicenne raises €16 million, Galapagos advances AbbVie-partnered drug and more.

BioLineRx has bought Agalimmune to expand its immuno-oncology pipeline. The takeover adds the synthetic alpha-gal immunotherapy AGI-134 to BioLineRx’s pipeline…

Former FDA commissioner Robert Califf, who was not asked back into his role by President Donald Trump, has become the new chair of the newly formed People-…

Quiet upstart BioClin Therapeutics has raised $30 million in a Series B funding round, taking its total to $59 million since its founding, as it aims to push…

Novartis’ phase 3 trial of serelaxin in acute heart failure has missed its primary endpoint.

Neurocrine Biosciences has published a journal paper about its phase 3 trial of tardive dyskinesia candidate Ingrezza.

Shares in Cerulean Pharma nosedived yesterday after the company agreed to sell off its anticancer assets at a bargain basement price and merge with Daré…

Biotech